Biomarker for Patients With Fabry Disease (BioFabry)

NCT02778295 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-02-13

No results posted yet for this study

Summary

Development of a new mass spectrography-based biomarker for the early and sensitive diagnosis of Fabry disease from the blood

Conditions

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Peter Bauer, Prof. · Centogene GmbH

Eligibility

Min Age
2 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Germany
  • India
  • Sri Lanka

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02778295 on ClinicalTrials.gov